Xeris Biopharma (NASDAQ:XERS) and Addex Therapeutics (NASDAQ:ADXN) Head-To-Head Contrast

Xeris Biopharma (NASDAQ:XERSGet Free Report) and Addex Therapeutics (NASDAQ:ADXNGet Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Earnings & Valuation

This table compares Xeris Biopharma and Addex Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xeris Biopharma $163.91 million 2.20 -$62.26 million ($0.47) -5.17
Addex Therapeutics $1.83 million 5.21 -$11.76 million ($18.33) -0.49

Addex Therapeutics has lower revenue, but higher earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Xeris Biopharma has a beta of 2.68, indicating that its share price is 168% more volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500.

Profitability

This table compares Xeris Biopharma and Addex Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Xeris Biopharma -37.58% -16,662.63% -19.58%
Addex Therapeutics -644.66% -277.56% -156.81%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Xeris Biopharma and Addex Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xeris Biopharma 0 0 4 0 3.00
Addex Therapeutics 0 1 0 0 2.00

Xeris Biopharma currently has a consensus price target of $4.63, indicating a potential upside of 90.33%. Given Xeris Biopharma’s stronger consensus rating and higher probable upside, research analysts clearly believe Xeris Biopharma is more favorable than Addex Therapeutics.

Insider & Institutional Ownership

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 4.6% of Xeris Biopharma shares are owned by insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Xeris Biopharma beats Addex Therapeutics on 9 of the 14 factors compared between the two stocks.

About Xeris Biopharma

(Get Free Report)

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

About Addex Therapeutics

(Get Free Report)

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.